Varied Analyst Comments On OncoSec Medical Incorporated (ONCS), Repligen Corporation (RGEN)

OncoSec Medical Incorporated (NASDAQ:ONCS) trading capacity remained 2.22 million shares during the last session. However, the volume average of the last three months is 0.59 million shares. The stock opened the day at $1.08, and settled at $1.14 by the end to experience a -0.87% change.

OncoSec Medical Incorporated (ONCS) Analyst Opinion

OncoSec Medical Incorporated has a consensus outperform rating from 4 Wall Street analysts, and the number of shares currently sold short amount to at least 3.16% of shares outstanding. The stock spiked 16.39% last month and is down -7.32 this year. Wall Street is only getting more bullish on the stock, with 4 of analysts who cover ONCS having a buy-equivalent rating. Analysts have placed a $5 price target on OncoSec Medical Incorporated, suggesting a 338.6% gain from recent close. It’s currently trading about -45.19% below its 52-week high.

OncoSec Medical Incorporated (NASDAQ:ONCS) Intraday View

This stock (ONCS) is ahead of its 52-week low with 29.55%. Its last month’s stock price volatility remained 11.58% which for the week stands at 11.98%. The share price has moved forward from its 20 days moving average, trading at a distance of 3.03% and stays 10.77% away from its 50 days moving average. Over the last five days, shares have faced -11.63% losses and now is down -0.06% since hitting its 200-day moving average of $1.06. OncoSec Medical Incorporated (ONCS) has made its way to a 12-month decline of -35.53%.

Turning to Repligen Corporation (NASDAQ:RGEN), its shares were trading at $37.62 a gain of $0.62, on the trading floor. The stock, after opening at $36.92, touched a high of $37.65 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.8. Repligen Corporation has 3 buy ratings, 2 holds and 0 sells even after the stock tumbled -19.63% from its high of $ 46.81 to a $1.6 billion market value through last close.

Repligen Corporation (RGEN) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 1.83 to 1.83 during a month. Analysts set a 12-month price target of $46.8 a share. The target implies a 24.4% spike from where the shares are currently trading. Also, the current price highlights a discount of 32.91% to analysts’ high consensus price target.

Repligen Corporation (NASDAQ:RGEN) Intraday Trading

The counter witnessed a trading volume of 0.27 million shares versus an average volume of 0.38 million shares during last trading session. Its last month’s stock price volatility remained 2.89% which for the week approaches 3.1%. The lowest price the stock reached in the last trading day was $36.06 and compares with the $26.16 52-week low. The stock recovered 43.81% since its low point and has performed 22.06% year-to-date.

Previous articleWall Street Analyst Actions To Watch: Biogen Inc. (BIIB), Intellia Therapeutics Inc. (NTLA)
Next articleAnalyst Opinion On How To Bet On Immunomedics, Inc. (IMMU), Loxo Oncology, Inc. (LOXO)